[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564024":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":25,"collaborators":27,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"Asklepios proresearch","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Double immune checkpoint inhibitor",null,"* Histologically or cytologically confirmed stage IV NSCLC without EGFR sensitizing mutations or ALK translocations OR\n* Histologically or cytologically confirmed advanced, malignant pleural mesothelioma\n* Eligible for double immune checkpoint inhibition with an anti PD1\u002FL1 inhibitor and a CTLA-4 inhibitor with or without chemotherapy according to current guidelines and SmPC",{"label":13,"type":10,"description":14,"interventionNames":10},"Immunotherapy with PD1\u002FL1 inhibitor","* Histologically or cytologically confirmed stage IV NSCLC without EGFR sensitizing mutations or ALK translocations\n* Eligible for treatment with an anti-PD-1\u002FL1 inhibitor with or without chemotherapy according to current guidelines and SmPCs",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Nele Geßler","CONTACT","+49 40 1818853160","n.gessler@asklepios.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Dagmar Pilz","+49 40 1818 853160","da.pilz@asklepios.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[28,31],{"name":29,"class":30},"Q1.6 B.V.","UNKNOWN",{"name":32,"class":33},"Medical University of Vienna","OTHER","100564024","cancer-patient-remote-monitoring-for-timely-communication-study-100564024",false,"NCT06623786","Cancer Patient Remote Monitoring for Timely Communication Study","CONNECT","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Age \\> 18 years at the time of study entry\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Life expectancy \\> 6 months\n* Patient is able and willing to use smart phone and a wearable device\u002Ftechnology\u002Fsensor\n\nExclusion Criteria:\n\n* Previous systemic treatment for metastatic or locally advanced disease","ALL","18 Years",{"count":44,"type":45},100,"ESTIMATED","OBSERVATIONAL","The study is designed as a prospective, single-arm observational, mixed-method study. Patients with stage IV NSCLC or inoperable mesothelioma will be included and will be treated with immunotherapy according to current guidelines and standard of care. Patients may receive either a PD1\u002FL1 inhibitor monotherapy or, if indicated, together with a CTLA4 inhibitor. Immunotherapy may be administered alone or together with chemotherapy as per site standard\u002Fphysician's choice. Patients will be given access to a mobile app. Patients will receive daily questions via the app to assess immune-related adverse events between clinic visits and their well-being.",[49],"NSCLC Stage IV","NOT_YET_RECRUITING","2024-09-30",{"date":53,"type":54},"2024-10-02","ACTUAL",{"date":56,"type":45},"2024-10",{"date":58,"type":45},"2026-04",{"name":5,"class":6}]